Serum levels of basic fibroblast growth factor reflect disseminated disease in patients with testicular germ cell tumors

被引:28
作者
Bentas, W [1 ]
Beecken, WD [1 ]
Glienke, W [1 ]
Binder, J [1 ]
Schuldes, H [1 ]
机构
[1] Univ Frankfurt, Dept Urol & Pediat Urol, D-60590 Frankfurt, Germany
来源
UROLOGICAL RESEARCH | 2003年 / 30卷 / 06期
关键词
testicular germ cell tumor; angiogenesis; angiogenic factors;
D O I
10.1007/s00240-002-0288-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The potential role of angiogenesis stimulators in the pathogenesis of different tumor entities has been confirmed in several studies. We measured the serum levels of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) in 51 patients with testicular germ cell tumors and in 39 healthy volunteers. Serum concentrations of bFGF, VEGF and PDGF-AB were determined by enzyme-linked immunosorbent assay. The median serum bFGF level for tumor patients was 3.46 pg/ml (range 0-61.6) compared to 0.7 pg/ml (0-11) in the control group (P<0.01). In patients with metastatic disease, the median serum bFGF level was 10.3 pg/ml (0-61.6) in contrast to 2.8 pg/ml (0-50) in patients with localized disease (P<0.01). The median serum VEGF and PDGF levels were 270 pg/ml (0-1,903) and 37,837 pg/ml (9,075-108,800), respectively, for tumor patients and 200 pg/ml (44-585) and 23,000 pg/ml (4,250-70,650) in the control group (P<0.05). Our data suggest that angiogenesis, as reflected by serum concentrations of bFGF, VEGF and PDGF, plays a functional role in the growth and progression of testicular germ cell tumors.
引用
收藏
页码:390 / 393
页数:4
相关论文
共 24 条
  • [1] ALBERS P, 1995, MODERN PATHOL, V8, P492
  • [2] Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-α and -β during human testicular development and disease
    Basciani, S
    Mariani, S
    Arizzi, M
    Ulisse, S
    Rucci, N
    Jannini, EA
    Della Rocca, C
    Manicone, A
    Carani, C
    Spera, G
    Gnessi, L
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (05) : 2310 - 2319
  • [3] Brattström D, 1998, ANTICANCER RES, V18, P1123
  • [4] Chaudhary R, 1999, ANTICANCER RES, V19, P3479
  • [5] Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer
    Faridi, A
    Rudlowski, C
    Biesterfeld, S
    Schuh, S
    Rath, W
    Schröder, W
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2002, 198 (01) : 1 - 5
  • [6] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [7] FOLKMAN J, 1989, J NATL CANCER I, V82, P4
  • [8] Fukuda S, 1999, CANCER, V85, P1323, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1323::AID-CNCR15>3.0.CO
  • [9] 2-G
  • [10] Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
    Hanahan, D
    Folkman, J
    [J]. CELL, 1996, 86 (03) : 353 - 364